Literature DB >> 3307643

Comparison of intranasal and oral desmopressin for nocturnal enuresis.

A Fjellestad-Paulsen, S Wille, A S Harris.   

Abstract

A single blind dose response study of the effects of treatment with tablets containing 50-400 micrograms of desmopressin was conducted in 15 children with primary nocturnal enuresis. A dose response effect was seen, with the 100, 200, and 400 micrograms doses resulting in significantly more dry nights than when a placebo was used. The response after 200 micrograms was significantly different from that after 100 micrograms (p less than 0.02) but not from that after 400 micrograms. A randomised, double blind, double dummy, cross over study was then carried out in 30 children to compare the effects of a 20 micrograms dose given through a nasal pipette, a 200 micrograms tablet, and a placebo. The numbers of dry nights were significantly greater during both periods of treatment with desmopressin when compared with that using placebo, but there were no differences between the methods of taking the drug. After oral and nasal treatment 41% and 52%, respectively, of the patients improved by more than 50%. Nine children (31%) remained completely dry after treatment.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3307643      PMCID: PMC1779260          DOI: 10.1136/adc.62.7.674

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  17 in total

1.  Diurnal variation of plasma vasopressin in man.

Authors:  C P George; F H Messerli; J Genest; W Nowaczynski; R Boucher; M Kuchel Orofo-Oftega
Journal:  J Clin Endocrinol Metab       Date:  1975-08       Impact factor: 5.958

2.  Desmopressin in the management of nocturnal enuresis in children: a double-blind study.

Authors:  M Birkásová; O Birkás; M J Flynn; J H Cort
Journal:  Pediatrics       Date:  1978-12       Impact factor: 7.124

3.  Observations on the intestinal absorption of some oligopeptides of methionine and glycine in the rat.

Authors:  D M Matthews; M T Lis; B Cheng; R F Crampton
Journal:  Clin Sci       Date:  1969-12       Impact factor: 6.124

4.  Desmopressin as a treatment for enuresis.

Authors:  S B Dimson
Journal:  Lancet       Date:  1977-06-11       Impact factor: 79.321

5.  Management of nocturnal enuresis with a vasopressin analogue.

Authors:  P Terho; M Kekomäki
Journal:  J Urol       Date:  1984-05       Impact factor: 7.450

6.  DDAVP for adult enuresis--a preliminary report.

Authors:  P D Ramsden; J R Hindmarsh; D A Price; W K Yeates; J D Bowditch
Journal:  Br J Urol       Date:  1982-06

7.  Desmopressin in nocturnal enuresis.

Authors:  M Aladjem; R Wohl; H Boichis; S Orda; D Lotan; S Freedman
Journal:  Arch Dis Child       Date:  1982-02       Impact factor: 3.791

8.  Urinary levels of antidiuretic hormone in nocturnal enuresis.

Authors:  V N Puri
Journal:  Indian Pediatr       Date:  1980-08       Impact factor: 1.411

9.  DDAVP and urine osmolality in refractory enuresis.

Authors:  S B Dimson
Journal:  Arch Dis Child       Date:  1986-11       Impact factor: 3.791

10.  DDAVP in childhood nocturnal enuresis.

Authors:  T Tuvemo
Journal:  Acta Paediatr Scand       Date:  1978-11
View more
  13 in total

Review 1.  Lymphoma metastasizing to the pituitary: an unusual presentation of a treatable disease.

Authors:  C Megan Ogilvie; Sarah Payne; Jane Evanson; T Andrew Lister; Ashley B Grossman
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

2.  The role of urine osmolality and ions in the pathogenesis of primary enuresis nocturna and in the prediction of responses to desmopressin and conditioning therapies.

Authors:  Tolga Unüvar; Ferah Sönmez
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

Review 3.  Hyponatremia in patients with nocturnal enuresis treated with DDAVP.

Authors:  W L Robson; J P Nørgaard; A K Leung
Journal:  Eur J Pediatr       Date:  1996-11       Impact factor: 3.183

4.  Dangers of intranasal desmopressin for nocturnal enuresis.

Authors:  M F Bamford; G Cruickshank
Journal:  J R Coll Gen Pract       Date:  1989-08

5.  Claiming desmopressin therapeutic equivalence in children requires pediatric data: a population PKPD analysis.

Authors:  Robin Michelet; Lien Dossche; Charlotte Van Herzeele; Jan Van Bocxlaer; An Vermeulen; Johan Vande Walle
Journal:  Eur J Clin Pharmacol       Date:  2017-12-03       Impact factor: 2.953

6.  An Integrated Paediatric Population PK/PD Analysis of dDAVP: How do PK Differences Translate to Clinical Outcomes?

Authors:  Robin Michelet; Lien Dossche; Charlotte Van Herzeele; Pauline De Bruyne; Elke Gasthuys; Jan Van Bocxlaer; Johan Vande Walle; An Vermeulen
Journal:  Clin Pharmacokinet       Date:  2020-01       Impact factor: 6.447

Review 7.  Side effects and complications of treatment with desmopressin for enuresis.

Authors:  W L Robson; A K Leung
Journal:  J Natl Med Assoc       Date:  1994-10       Impact factor: 1.798

Review 8.  Comparative tolerability of drug therapies used to treat incontinence and enuresis.

Authors:  R G Owens; M M Karram
Journal:  Drug Saf       Date:  1998-08       Impact factor: 5.606

Review 9.  Comparative tolerability of drug treatment for nocturnal enuresis in children.

Authors:  Dominik Müller; Charles C Roehr; Paul Eggert
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 10.  Drug therapy for nocturnal enuresis. Current treatment recommendations.

Authors:  K Miller; B Atkin; M L Moody
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.